In addition, there was no significant difference in the incidence of adverse events between subcutaneous and intravenous administration, and it was safe and tolerable in HER2-positive early/locally advanced breast cancer (EBC/LABC) (Zambetti et al., 1990; De Sanctis et al., 2021). This evidence concerns the gene ERBB2 and breast cancer.